[1]王兆雄,齐世欣,刘艳丽,等.玻璃体腔注射康博西普治疗眼底病的安全性及有效性[J].医学信息,2020,33(19):104-106.[doi:10.3969/j.issn.1006-1959.2020.19.031]
　WANG Zhao-xiong,QI Shi-xin,LIU Yan-li,et al.Safety and Effectiveness of Intravitreal Injection of Conbercept in the Treatment of Fundus Disease[J].Medical Information,2020,33(19):104-106.[doi:10.3969/j.issn.1006-1959.2020.19.031]
点击复制

玻璃体腔注射康博西普治疗眼底病的安全性及有效性()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年19期
页码:
104-106
栏目:
临床研究
出版日期:
2020-10-01

文章信息/Info

Title:
Safety and Effectiveness of Intravitreal Injection of Conbercept in the Treatment of Fundus Disease
文章编号:
1006-1959（2020）19-0104-03
作者:
王兆雄; 齐世欣; 刘艳丽; 于建国
天津市宝坻区人民医院眼科/天津医科大学宝坻临床学院，天津 301800
Author(s):
WANG Zhao-xiong; QI Shi-xin; LIU Yan-li; YU Jian-guo
Department of Ophthalmology,People’s Hospital of Baodi District/Baodi Clinical College of Tianjin Medical University, Tianjin 301800,China
关键词:
玻璃体; 注射; 康博西普; 眼底病
Keywords:
Vitreous; Injection; Conbosicept; Fundus disease
分类号:
R77
DOI:
10.3969/j.issn.1006-1959.2020.19.031
文献标志码:
A
摘要:
目的 探究玻璃体腔注射康博西普对眼底病临床安全性和有效性的影响。方法 选取2018年1月~2019年7月在我院治疗的68例眼底病患者为研究对象，采用随机数字表法分为对照组和观察组，各34例。对照组给予常规对症治疗，观察组在对照组基础上给予玻璃体腔注射康博西普治疗，比较两组临床治疗总有效率、临床症状改善时间、裸眼视力、黄斑中心凹视网膜厚度（CMT）、眼内压（IOP）及并发症发生情况。结果 观察组治疗总有效率为97.05%，高于对照组的88.23%，差异有统计学意义（P＜0.05）；观察组平均视网膜水肿、新生血管、视网膜出血消失和视网膜厚度恢复正常时间均短于对照组，差异有统计学意义（P＜0.05）；治疗后，观察组裸眼视力高于对照组，CMT、IOP均小于对照组，差异有统计学意义（P＜0.05）；观察组并发症发生率为5.88%，与对照组的8.82%比较，差异无统计学意义（P＞0.05）。结论 玻璃体腔注射康博西普治疗眼底病总有效率高，可缩短临床症状改善时间，促进视力恢复，减小CMT和降低眼内压，应用安全性良好。
Abstract:
Objective To explore the effect of intravitreal injection of Conbosicept on the clinical safety and effectiveness of fundus diseases.Methods A total of 68 patients with fundus disease treated in our hospital from January 2018 to July 2019 were selected as the research objects. They were divided into control group and observation group by random number table method, with 34 cases in each group. The control group was given conventional symptomatic treatment, and the observation group was given intravitreal injection of Conbercept on the basis of the control group. The total effective rate of clinical treatment, clinical symptom improvement time, naked vision, macular foveal retinal thickness (CMT), eye Internal pressure (IOP) and complications.Results The total effective rate of treatment in the observation group was 97.05%, which was higher than 88.23% in the control group,the difference was statistically significant (P＜0.05). The average retinal edema, neovascularization, disappearance of retinal hemorrhage, and retinal thickness return to normal in the observation group were shorter than those in the control group,the difference was statistically significant (P＜0.05); after treatment, the naked eye vision of the observation group was higher than that of the control group, CMT, IOP All were smaller than the control group, the difference was statistically significant (P＜0.05); the complication rate in the observation group was 5.88%, compared with 8.82% in the control group, the difference was not statistically significant (P>0.05).Conclusion Intravitreal injection of Conbosicept in the treatment of ocular fundus disease had a high overall effective rate, which could shorten the time of clinical symptom improvement, promote visual recovery, reduce CMT and lower intraocular pressure, and had good application safety.

参考文献/References:

[1]周美兰,韩永钊,杨瑛,等.玻璃体腔内注射康柏西普治疗继发性黄斑水肿疗效观察[J].中国医学创新,2016,13(31):134-137. [2]卢霞,朱怡,陈贵芹,等.71例玻璃体腔注射康博西普治疗渗出型老年黄斑变性临床效果观察[J].医学新知杂志,2016,26(5):380-382. [3]宋蔚,赵帅,郅瑛,等.康柏西普玻璃体腔注射治疗渗出型老年性黄斑变性的疗效[J].国际眼科杂志,2016,16(7):1310-1312. [4]李铮,栗小丽,王家良,等.分析康柏西普玻璃体腔注射联合视网膜光凝治疗糖尿病视网膜病变的疗效[J].糖尿病新世界,2016,19(19):21-22. [5]蒋云婕,张雪彤,周丹虹.玻璃体腔分别注射康柏西普与曲安奈德治疗糖尿病视网膜病变对比[J].临床医药文献杂志,2017,4(61):11897-11898. [6]殷小敏.玻璃体腔注射康博西普治疗眼底病的临床疗效[J].临床医药文献杂志,2017,4(77):15184-15185. [7]窦禹.术前玻璃体腔注射雷珠单抗对增生型糖尿病视网膜病变患眼玻璃体切割手术后视力的影响[J].中国药物经济学,2017,12(1):45-47. [8]连海燕,宋艳萍,丁琴,等.康柏西普与雷珠单抗玻璃体腔注射治疗视网膜中央静脉阻塞黄斑水肿短期疗效对比观察[J].中华眼底病杂志,2016,32(4):367-371. [9]孙京晶.眼底病患者应用玻璃体腔注射Avastin治疗的临床疗效及可行性研究[J].中国疗养医学,2017,26(7):758-759. [10]Bonnin S,Sandali O,Bonnel S,et al.Vitrectomy with internal limiting membrane peeling for tractional and nontractional diabetic macular edema:Long-term Results of a Comparative Study[J].Retina,2015,35(5):921-928. [11]张妍春,任秀瑜,康紫薇,等.玻璃体切除术联合雷珠单抗玻璃体注射治疗增殖性糖尿病视网膜病变的临床研究[J].海南医学,2018,29(23):3296-3299. [12]张菁,蔡小军,陈晓敏,等.玻璃体腔注射康柏西普联合视网膜激光光凝治疗视网膜分支静脉阻塞继发黄斑水肿疗效观察[J].中华眼底病杂志,2015,31(1):22-26. [13]张聪,许贺,徐丽.玻璃体腔注射Ranibizumab联合激光治疗BRVO继发黄斑水肿的观察[J].国际眼科杂志,2014,32(8):1399-1402. [14]韩姬,王玲,刘伟仙,等.康柏西普玻璃体腔注射对糖尿病视网膜病变患者视力的影响[J].中国全科医学,2015,18(5):502-506. [15]毕燃,贾彩华,于越,等.康柏西普治疗视网膜静脉阻塞黄斑水肿的临床观察[J].赤峰学院学报(自然科学版),2014,30(12上):71-73.

更新日期/Last Update: 1900-01-01